Response rates with Ven-Aza or Pbo-Aza in favorable-, intermediate-, and adverse-risk groups. CR/CRi rate in patients treated with Ven-Aza or Pbo-Aza by (A) ELN 2017 and (B) ELN 2022. OS in patients treated with Ven-Aza or Pbo-Aza in the ELN 2022 (C) favorable-, (D) intermediate-, and (E) adverse-risk groups. Aza, azacitidine; NR, not reached; Pbo, placebo; Ven, venetoclax.